The Form 4 filing was filed on November 2, 2026, for a trade dated October 30, 2026. This form reports changes in an insider's stock ownership. Fredrik Widman serves as Intuitive Surgical's vice president and corporate controller.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-30 |
| Date of Latest Transaction | 2026-10-30 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 5,448 |
| Price | $436.06 |
| Total Transaction Value | $2,375,628.18 |
| Insider | |
| Ticker Symbol | ISRG |
| Company | INTUITIVE SURGICAL INC |
| Insider Name | Widman Fredrik |
| Insider Title | VP Corporate Controller |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 1,026 |
| Position Size Change | 84.15% |
| Filing | |
| Filing Date | 2026-11-02 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S, which identifies a sale. The reported activity consists of one transaction involving 5,448 Intuitive Surgical (ISRG) shares.
What was the average price of the transaction?
The average price was $436.0551 per share. Rounded to cents, that is $436.06 per share.
How did this transaction affect the insider's holdings?
Fredrik Widman sold 5,448 shares and reported 1,026 shares owned afterward. Those figures show a balance of 6,474 shares before the sale. He sold 84.15% of that balance.
What's the total transaction value?
The reported total value was $2,375,628.1848, or $2,375,628.18 rounded to cents. That amount covers the single reported sale.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The available details do not establish whether the reference covers this sale or applies to the filing more broadly. Footnote text was not available to confirm its scope. The plan's start date, trading schedule, and other terms remain unknown.
For research purposes only; not investment advice.